These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 39276771)

  • 1. Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma.
    Chiffelle J; Barras D; Pétremand R; Orcurto A; Bobisse S; Arnaud M; Auger A; Rodrigo BN; Ghisoni E; Sauvage C; Saugy D; Michel A; Murgues B; Fahr N; Imbimbo M; Ochoa de Olza M; Latifyan S; Crespo I; Benedetti F; Genolet R; Queiroz L; Schmidt J; Homicsko K; Zimmermann S; Michielin O; Bassani-Sternberg M; Kandalaft LE; Dafni U; Corria-Osorio J; Trueb L; Dangaj Laniti D; Harari A; Coukos G
    Immunity; 2024 Oct; 57(10):2466-2482.e12. PubMed ID: 39276771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
    Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
    Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma.
    Kristensen NP; Heeke C; Tvingsholm SA; Borch A; Draghi A; Crowther MD; Carri I; Munk KK; Holm JS; Bjerregaard AM; Bentzen AK; Marquard AM; Szallasi Z; McGranahan N; Andersen R; Nielsen M; Jönsson GB; Donia M; Svane IM; Hadrup SR
    J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 34813506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
    Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
    J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
    Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
    Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
    Dudley ME; Gross CA; Somerville RP; Hong Y; Schaub NP; Rosati SF; White DE; Nathan D; Restifo NP; Steinberg SM; Wunderlich JR; Kammula US; Sherry RM; Yang JC; Phan GQ; Hughes MS; Laurencot CM; Rosenberg SA
    J Clin Oncol; 2013 Jun; 31(17):2152-9. PubMed ID: 23650429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence and enrichment of dominant T cell clonotypes in expanded tumor-infiltrating lymphocytes of breast cancer.
    Ham B; Kim SY; Kim YA; Han D; Park T; Cha S; Jung S; Kim JH; Park G; Gong G; Lee HJ; Shin J
    Br J Cancer; 2024 Jul; 131(1):196-204. PubMed ID: 38750113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.
    Dudley ME; Wunderlich JR; Shelton TE; Even J; Rosenberg SA
    J Immunother; 2003; 26(4):332-42. PubMed ID: 12843795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
    Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
    PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between T cell receptor clonotype and PD-1 expression of tumor-infiltrating lymphocytes in colorectal cancer.
    Sukegawa K; Shitaoka K; Hamana H; Kobayashi E; Miyahara Y; Fujii K; Tsuda K; Saeki S; Nagata T; Ozawa T; Saito S; Fujii T; Muraguchi A; Shiku H; Kishi H
    Eur J Immunol; 2020 Oct; 50(10):1580-1590. PubMed ID: 32441316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.
    Huang J; Khong HT; Dudley ME; El-Gamil M; Li YF; Rosenberg SA; Robbins PF
    J Immunother; 2005; 28(3):258-67. PubMed ID: 15838383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer.
    Krishna S; Lowery FJ; Copeland AR; Bahadiroglu E; Mukherjee R; Jia L; Anibal JT; Sachs A; Adebola SO; Gurusamy D; Yu Z; Hill V; Gartner JJ; Li YF; Parkhurst M; Paria B; Kvistborg P; Kelly MC; Goff SL; Altan-Bonnet G; Robbins PF; Rosenberg SA
    Science; 2020 Dec; 370(6522):1328-1334. PubMed ID: 33303615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
    Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
    Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIL the end: Tracking T cell clonotype dynamics during adoptive cell therapy.
    Buzzai AC; Tüting T
    Immunity; 2024 Oct; 57(10):2260-2262. PubMed ID: 39383841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoantigen-specific CD4
    Hall MS; Teer JK; Yu X; Branthoover H; Snedal S; Rodriguez-Valentin M; Nagle L; Scott E; Schachner B; Innamarato P; Hall AM; Blauvelt J; Rich CJ; Richards AD; Ceccarelli J; Langer TJ; Yoder SJ; Beatty MS; Cox CA; Messina JL; Abate-Daga D; Mule JJ; Mullinax JE; Sarnaik AA; Pilon-Thomas S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37802604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T Cells Expanded from PD-1
    Li T; Zhao L; Yang Y; Wang Y; Zhang Y; Guo J; Chen G; Qin P; Xu B; Ma B; Zhang F; Shang Y; Li Q; Zhang K; Yuan D; Feng C; Ma Y; Liu Z; Tian Z; Li H; Wang S; Gao Q
    Cancer Res; 2021 Apr; 81(8):2184-2194. PubMed ID: 33408117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells.
    Martinez-Usatorre A; Carmona SJ; Godfroid C; Yacoub Maroun C; Labiano S; Romero P
    Front Immunol; 2020; 11():340. PubMed ID: 32174925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
    Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
    J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
    Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
    Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient.
    Wieland A; Kamphorst AO; Adsay NV; Masor JJ; Sarmiento J; Nasti TH; Darko S; Douek DC; Xue Y; Curran WJ; Lawson DH; Ahmed R
    Cancer Immunol Immunother; 2018 Nov; 67(11):1767-1776. PubMed ID: 30167863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.